DOI: 10.36347/sjams.2018.v06i07.057

Pages: 2931-2938

Elevated serum cystatin-C in the first few hours of hospitalization for acute coronary syndrome (ACS) is an independent predictor of major adverse cardiovascular event (MACE), especially of heart failure, either in-hospital or during follow-up. We conducted this prospective study to analyze the prognostic value of Serum Cystatin C in patients with ACS. A total of sixty-six patients with ACS were enrolled in the study. Serum cystatin C were measured immediately after hospitalization, before discharge and at 6 months of follow up. Patients were divided into two groups according to serum cystatin C concentration at hospitalization as follows: group a - serum cystatin C ≤ 1.5; and group B- serum cystatin C > 1.5 mg/dl. Coronary angiogram was performed for the entire study population. Study end point was the MACE which included angina, re-infarction, stent thrombosis, stent re-stenosis; urgent revascularization and mortality at index and at six months follow up. Serum cystatin C concentration doesn`t differ in different forms of ACS presentation. Higher basal serum cystatin C level is associated with higher killip class at presentation. Lower basal serum cystatin C level is associated with single vessel coronary artery disease (SVD in group A with serum cystatin C ≤ 1.5 mg/dl, p < 0.05). Higher serum cystatin C concentration at presentation of ACS is directly proportional in predicting the MACE outcome and is independent of renal function. Therefore we can conclude that serum cystatin C concentration is a novel marker in the early risk stratification of ACS patients.